AbbVie agrees to buy Apogee Therapeutics in about $11 billion deal

AbbVie said it will acquire Apogee Therapeutics in an all-cash deal valued at about $10.9 billion, or about $11 billion rounded, in a move that adds a late-stage immunology asset to its pipeline.

The transaction, reported by multiple outlets on June 22, 2026, is set at $135.11 a share and gives AbbVie control of Apogee’s lead candidate, zumilokibart. Reports said Apogee shareholders will receive a large premium, though estimates varied by outlet, with some putting it around 49% and others closer to 60%.

Apogee shares jumped sharply on the news, and AbbVie stock also rose as investors assessed the fit with the company’s existing immunology franchise.

Deal terms and timing

The reports all pointed to the same basic structure: a cash acquisition at $135.11 per share that values Apogee at roughly $10.9 billion. Barron’s said the boards of both companies approved the deal and that closing is expected in the third quarter of 2026.

The earliest confirmed publication in the research packet came from the Financial Times at 11:48 UTC on June 22. Later same-day coverage from the Wall Street Journal, MarketWatch, Barron’s and Investors.com broadly confirmed the terms and the strategic rationale.

The transaction still needs the remaining merger steps before it closes, so the deal is announced but not complete.

Why AbbVie wants Apogee

The acquisition is aimed at reinforcing AbbVie’s immunology business beyond Skyrizi and Rinvoq, two of its most important growth products.

AbbVie has been working to diversify after Humira lost U.S. patent protection in 2023. Buying Apogee gives it another potential successor asset in the same therapeutic area where it already has commercial strength.

That matters because the deal is not a move into a new category. It is a bet that AbbVie can extend its leadership in inflammation and immunology by adding a drug candidate that could eventually help support revenue after older products fade.

The asset at the center

Apogee’s lead drug is zumilokibart, an experimental immunology treatment being developed for atopic dermatitis and other inflammatory conditions.

Market reports described it as a long-acting candidate and said a phase-three trial is expected later in the year. That late-stage profile helps explain why AbbVie was willing to pay up now rather than wait for more de-risking.

The acquisition also fits a broader pattern in biotech M&A, where larger drugmakers are buying pipeline assets to fill future gaps and reduce dependence on a small number of blockbusters.

Market reaction and investor stakes

Apogee shareholders are getting a sizable immediate premium in cash, which is the clearest near-term winner in the deal.

For AbbVie, the question is whether the purchase price will be justified by the eventual commercial and clinical performance of zumilokibart. Investors are likely to focus on whether the program can broaden AbbVie’s immunology mix without requiring a lengthy integration period or unexpected development setbacks.

The deal also underscores the stakes for AbbVie’s long-term revenue profile. With competition building around its existing immunology portfolio, the company is paying now for a possible successor asset rather than waiting for the pipeline to mature on its own.

What comes next

The next milestones are the formal merger materials, any SEC filing details and management commentary on development timing.

Investors will also be watching for more specific guidance on the path for zumilokibart, including AbbVie’s plans for the asset inside its broader immunology strategy.

For now, the message from the deal is clear: AbbVie is spending heavily to buy time, growth and optionality in one of its core therapeutic areas.